Burlington, Massachusetts, December 6, 2022 – MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, has acquired Massachusetts-based Erbi Biosystems, a…

BOSTON, May 31, 2022 -- Erbi Biosystems, Inc., a global leader in dose-scale, fully automated microbioreactors for cell therapy development and manufacturing, today announced the appointment of Brad Hamilton to…

Erbi Biosystems joins cell manufacturing research initiative to develop the next generation of cell therapies April 26, 2022, Boston, MA and Atlanta, GA: Erbi Biosystems has joined the National Science…

KTH Royal Institute of Technology, Karolinska University Hospital and Lund University partner with Erbi Biosystems to develop intensified bioprocesses, covering biologics, gene and cell therapies. BOSTON and STOCKHOLM, March 23,…

Manufacturers of the only commercially available mL-scale bioreactor with fully automated True Perfusion™ capability, has secured additional funding to expand its solutions for cell therapy development and manufacturing CAMBRIDGE, Mass., Jan.…

WOBURN, Mass., Oct. 30, 2020  -- Erbi Biosystems, a transformative microfluidic bioprocess instrumentation company based on technology developed at MIT, announced today the closing of a finance round which brings the…